Abstract
Bortezomib (Velcade, formerly PS-341) represents the first proteasome inhibitor to have shown anti-tumor activity in both solid and haematological malignancies. It blocks activation of nuclear factor-kappa B (NF-κB), resulting in increased apoptosis, decreased angiogenic cytokine production, and inhibition of tumor cell adhesion to stroma. Additional mechanisms of action include c-Jun N-terminal kinase activation, effects on growth factor expression and antiangiogenic properties. Multiple myeloma is the prototype of cancer where bortezomib has shown marked in vitro activity, which was followed by rapid translation to phase I, II and III clinical trials, and resulted in accelerated approval by the FDA for the treatment of patients with relapsed refractory disease. Different clinical trials are currently ongoing in multiple myeloma as well as in many others haematologic and solid tumors (mantle cell and follicular non-Hodgkins lymphoma; peripheral T-cell lymphoma; Waldenströms macroglobulinemia, chronic lymphocytic leukemia; head and neck / gastroesophageal junction / stomach /colo-rectal / prostate / non-small cell lung cancer). This reviews focuses on the proteasome inhibition exerted by bortezomib, the first proteasome inhibitor to have shown anti-cancer activity in both solid and haematologic malignancies.
Keywords: Bortezomib, proteasome inhibition, anti-tumor activity
Recent Patents on Anti-Cancer Drug Discovery
Title: Bortezomib in the Treatment of Cancer
Volume: 1 Issue: 3
Author(s): Aldo M. Roccaro, Angelo Vacca and Domenico Ribatti
Affiliation:
Keywords: Bortezomib, proteasome inhibition, anti-tumor activity
Abstract: Bortezomib (Velcade, formerly PS-341) represents the first proteasome inhibitor to have shown anti-tumor activity in both solid and haematological malignancies. It blocks activation of nuclear factor-kappa B (NF-κB), resulting in increased apoptosis, decreased angiogenic cytokine production, and inhibition of tumor cell adhesion to stroma. Additional mechanisms of action include c-Jun N-terminal kinase activation, effects on growth factor expression and antiangiogenic properties. Multiple myeloma is the prototype of cancer where bortezomib has shown marked in vitro activity, which was followed by rapid translation to phase I, II and III clinical trials, and resulted in accelerated approval by the FDA for the treatment of patients with relapsed refractory disease. Different clinical trials are currently ongoing in multiple myeloma as well as in many others haematologic and solid tumors (mantle cell and follicular non-Hodgkins lymphoma; peripheral T-cell lymphoma; Waldenströms macroglobulinemia, chronic lymphocytic leukemia; head and neck / gastroesophageal junction / stomach /colo-rectal / prostate / non-small cell lung cancer). This reviews focuses on the proteasome inhibition exerted by bortezomib, the first proteasome inhibitor to have shown anti-cancer activity in both solid and haematologic malignancies.
Export Options
About this article
Cite this article as:
Roccaro M. Aldo, Vacca Angelo and Ribatti Domenico, Bortezomib in the Treatment of Cancer, Recent Patents on Anti-Cancer Drug Discovery 2006; 1 (3) . https://dx.doi.org/10.2174/157489206778776925
DOI https://dx.doi.org/10.2174/157489206778776925 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Upregulation of Focal Adhesion Kinase by 14-3-3ε via NFκB Activation in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Targeted Blood-to-Brain Drug Delivery – 10 Key Development Criteria
Current Pharmaceutical Biotechnology Biohybrid Membrane Systems for Testing Molecules and Stem Cell Therapy in Neuronal Tissue Engineering
Current Pharmaceutical Design Genetic Variants in Genes Involved in Mechanisms of Chemoresistance to Anticancer Drugs
Current Cancer Drug Targets Establishment of Cholinergic Neuron-like Cell Lines with Differential Vulnerability to Nitrosative Stress
Current Neurovascular Research Novel Anticancer Strategy Aimed at Targeting Shelterin Complexes by the Induction of Structural Changes in Telomeric DNA: Hitting two Birds with one Stone
Current Cancer Drug Targets Nanomedicine to Overcome Cancer Multidrug Resistance
Current Drug Metabolism ENaC in the Brain - Future Perspectives and Pharmacological Implications
Current Molecular Pharmacology Potentials of Hydrogels in Cancer Therapy
Current Cancer Therapy Reviews Pharmacological Strategies to Increase the Antitumor Activity of Methylating Agents
Current Medicinal Chemistry Identification of KEY lncRNAs and mRNAs Associated with Oral Squamous Cell Carcinoma Progression
Current Bioinformatics Application of Recombinant and Non-Recombinant Peptides in the Determination of Tumor Response to Cancer Therapy
Current Pharmaceutical Biotechnology The Efficacy and Mechanism of Proteasome Inhibitors in Solid Tumor Treatment
Recent Patents on Anti-Cancer Drug Discovery Genistein: A Phytoestrogen with Multifaceted Therapeutic Properties
Mini-Reviews in Medicinal Chemistry Algae Polysaccharides’ Chemical Characterization and their Role in the Inflammatory Process
Current Medicinal Chemistry Multitarget-Directed Ligands: Innovative Chemical Probes and Therapeutic Tools Against Alzheimer's Disease
Current Topics in Medicinal Chemistry Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance
Current Cancer Drug Targets Patent Selections
Recent Patents on Drug Delivery & Formulation Peptides to Target Tumor Vasculature and Lymphatics for Improved Anti-Angiogenesis Therapy
Current Cancer Drug Targets The Roles of Histone Demethylase UTX and JMJD3 (KDM6B) in Cancers: Current Progress and Future Perspectives
Current Medicinal Chemistry